Literature DB >> 8220893

Functional evidence for multiple receptor activation by kappa-ligands in the inhibition of spinal nociceptive reflexes in the rat.

J F Herrero1, P M Headley.   

Abstract

1. The evidence for kappa-receptor heterogeneity is equivocal. We have now investigated this question by comparing the effects of five putatively selective kappa-agonists. The parameters examined were: the relative potencies in depressing hindlimb flexor muscle reflexes to noxious pinch stimuli in both spinalized and sham-spinalized rats; the reversibility of these effects by naloxone; and the effects on blood pressure. 2. Two types of drug effect was discriminated. One drug group, represented by U-50,488, U-69,593 and PD-117,302, had a potency ratio between sham and spinalized rats approximately 10 fold lower than the other group, which comprised GR103545 and CI-977. 3. Under sham-spinalized conditions, CI-977 and GR103545 at high doses caused only sub-maximal reductions of spinal reflexes. U-50,488 was still active when superimposed on these high doses of GR103545. 4. Naloxone reversed all effects, but different doses were required between compounds, with GR103545 taking some 20 times higher doses of naloxone to cause reversal than did U-50,488. 5. The effects on mean arterial pressure were opposite between groups. 6. The results imply that more than one type of naloxone-sensitive non-mu opioid receptor must be involved in mediating these complex actions of ligands that have been claimed to be selective for kappa-receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220893      PMCID: PMC2176008          DOI: 10.1111/j.1476-5381.1993.tb13809.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Spinal effects of four injectable anaesthetics on nociceptive reflexes in rats: a comparison of electrophysiological and behavioural measurements.

Authors:  N A Hartell; P M Headley
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Spinal antinociceptive actions and naloxone reversibility of intravenous mu- and kappa-opioids in spinalized rats: potency mismatch with values reported for spinal administration.

Authors:  C G Parsons; D C West; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

3.  Characterisation of kappa-opioid binding sites in rat and guinea-pig spinal cord.

Authors:  M S Wood; F D Rodriguez; J R Traynor
Journal:  Neuropharmacology       Date:  1989-10       Impact factor: 5.250

4.  CI-977, a novel and selective agonist for the kappa-opioid receptor.

Authors:  J C Hunter; G E Leighton; K G Meecham; S J Boyle; D C Horwell; D C Rees; J Hughes
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

5.  Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.

Authors:  R B Rothman; V Bykov; B R de Costa; A E Jacobson; K C Rice; L S Brady
Journal:  Peptides       Date:  1990 Mar-Apr       Impact factor: 3.750

6.  Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulus.

Authors:  C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

7.  Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.

Authors:  J A Clark; L Liu; M Price; B Hersh; M Edelson; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

8.  kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat.

Authors:  G E Leighton; R E Rodriguez; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

9.  PD117302: a selective agonist for the kappa-opioid receptor.

Authors:  C R Clark; B Birchmore; N A Sharif; J C Hunter; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

10.  A series of novel, highly potent and selective agonists for the kappa-opioid receptor.

Authors:  A G Hayes; P J Birch; N J Hayward; M J Sheehan; H Rogers; M B Tyers; D B Judd; D I Scopes; A Naylor
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

View more
  4 in total

1.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

2.  kappa -opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action.

Authors:  S K Joshi; X Su; F Porreca; G F Gebhart
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

3.  Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

4.  Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.

Authors:  D I Brissett; J L Whistler; R M van Rijn
Journal:  Eur J Pain       Date:  2011-12-19       Impact factor: 3.931

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.